SS-31 (Elamipretide): Narrow FDA Approval and Indication-Specific Evidence

Reviewed for accuracy by the Gorilla Research Insights research team · 2026-07-04

MITOCHONDRIAL SCIENCE SS-31 (Elamipretide): Narrow FDA Approval and Indication-Specific Evidence SS-31, also called elamipretide, is a mitochondria-targeted tetrapeptide. FDA granted accelerated approval to one elamipretide drug product for a narrowly defined Barth syndrome population in 2025; evidence in other diseases remains mixed and indication-specific.

Mechanistic basis

Biophysical and preclinical work links SS-31 with cardiolipin-associated mitochondrial processes ^[1]. This provides a testable mechanism; it does not prove “mitochondrial repair,” anti-aging activity, or benefit across diseases.

Regulatory status

On September 19, 2025, FDA granted accelerated approval to Forzinity (elamipretide) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg ^[4]. The approval was based on an intermediate endpoint and requires a confirmatory trial to verify clinical benefit. This narrow approval does not establish efficacy in other conditions or equivalence of a separately supplied research material.

Human evidence

A randomized dose-escalation trial in 36 adults with primary mitochondrial myopathy evaluated short-term functional, biomarker, pharmacokinetic, and safety endpoints ^[2]. A later phase 2 trial in geographic atrophy did not meet its primary efficacy endpoints, although exploratory structural findings were reported ^[3]. These populations and endpoints are not interchangeable. The accurate conclusion is that elamipretide has controlled human evidence and one accelerated approval with a narrow indication, alongside important negative or inconclusive findings in other populations. The record does not support a general claim of improved energy, longevity, exercise capacity, or organ protection.

Research frontier

Open questions include whether the confirmatory Barth syndrome trial verifies clinical benefit, which other mitochondrial phenotypes are responsive, whether short-term biomarkers predict durable function, and how results vary by tissue and disease. Product identity also matters: a catalog research material is not established as equivalent to Forzinity or any trial drug.

Primary sources

• ^[1] Birk et al. Cardiolipin and SS-31 mitochondrial interactions . • ^[2] Karaa et al. Randomized trial in primary mitochondrial myopathy . • ^[3] ReCLAIM-2 investigators. Randomized phase 2 geographic-atrophy trial . • ^[4] U.S. Food and Drug Administration. Accelerated approval of Forzinity for a defined Barth syndrome population , 2025. Educational material only. It does not provide dosing or use advice, and it does not represent a research material as an FDA-approved drug product.